This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Medication Optimisation for Reducing Events in a Private Practice Setting (MORE)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2009 by Awenydd GmbH.
Recruitment status was:  Active, not recruiting
Information provided by:
Awenydd GmbH Identifier:
First received: April 2, 2008
Last updated: April 7, 2009
Last verified: April 2009

Using a prospective study design of two three month periods (before and after genotyping) in which the patients will self-monitor their health status and possible medical events it is hypothesized that it will be shown that patients having their medication altered to fit their genetic status and/or having their medication altered because of inherent interaction potential will have less recordable events after genotyping and medical analysis than before.

It is well known that ADRs (recordable adverse events to medication) are responsible for a large number of deaths and hospitalizations. Furthermore it is well recorded that genotyping of individual cytochrome P450 enzymes (2D6, 2C9, 2C19, among others) is directly related to a metabolic phenotype - fast metabolisers, slow metabolisers, intermediate and normal metabolisers. These differing phenotypes have altered metabolism of many medications and in a number of retrospective clinical trails it has been shown that ADRs and effect can be reduced/bettered through genotyping and alteration of medication.

Pharmacogenetic Analysis to Reduce Events.

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Study of the Pharmaco-Economic and Medical Effects of Optimising Medication Using Pharmacokinetic Pharmacogenomics and Medication Interaction Analysis in Private Practice.

Further study details as provided by Awenydd GmbH:

Primary Outcome Measures:
  • Reduction of reported events in the time frame. [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Reduction of total costs associated per patient in the time frame. [ Time Frame: 3 months ]

Estimated Enrollment: 500
Study Start Date: August 2008
Estimated Study Completion Date: October 2009
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Group A
Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Community sample.

Inclusion Criteria:

  • older than 18 years
  • not demented
  • 1 or more documented events in the previous 6 months.
  • more than one medication
  • multi-morbid

Exclusion Criteria:

  • demented
  • life expectancy less than 1 year
  • heart attack within the last 6 months
  • Marcumar® Therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00653653

Awenydd Gmbh
Köln, NRW, Germany, 50829
Sponsors and Collaborators
Awenydd GmbH
Study Director: Lee S Griffith, Ph.D. Awenydd GmbH
Principal Investigator: André Gessner, MD Ph.D. University of Erlangen-Nürnberg
  More Information

Chialda, L; Griffith, LS; Heinig, A; Pahl, A. Prospective use of CYP pharmacogenetics and medication analysis to facilitate improved therapy - a pilot study. Personalized Medicine (2008) 5(1): 37-35

Responsible Party: Dr. LS Griffith, awenydd Gene Diagnostic Identifier: NCT00653653     History of Changes
Other Study ID Numbers: AW_SH_08
Study First Received: April 2, 2008
Last Updated: April 7, 2009

Keywords provided by Awenydd GmbH:
adverse events
drug metabolism processed this record on August 22, 2017